Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition
2022 StandoutNobel
Hypoxia‐inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype
2016 StandoutNobel
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Colorectal cancer statistics, 2023
2023 Standout
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
2022 Standout
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
2012 StandoutNobel
Microenvironmental regulation of tumour angiogenesis
2017
Tumor angiogenesis: causes, consequences, challenges and opportunities
2019
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07)
2013
Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer
2011
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
Hepatocellular carcinoma
2016 Standout
Hepatocellular carcinoma
2018 Standout
A comprehensive map of molecular drug targets
2016 Standout
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
2007
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016
The role of liposomes in clinical nanomedicine development. What now? Now what?
2019 Standout
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling
2016
Burden of liver diseases in the world
2018 Standout
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
2012 Standout
Vessel co-option in cancer
2019
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Hypoxia-Inducible Factors: Master Regulators of Cancer Progression
2016 StandoutNobel
Hepatocellular carcinoma
2021 Standout
The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors
2016
Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors
2014
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
2014
Prodrugs—from Serendipity to Rational Design
2011
Delivery technologies for cancer immunotherapy
2019 Standout
Ten years of anti-vascular endothelial growth factor therapy
2016
Cancer-associated cachexia
2018 Standout
Antiangiogenic therapy—evolving view based on clinical trial results
2012
From Krebs to clinic: glutamine metabolism to cancer therapy
2016 Standout
ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: Thyroid effects of tyrosine kinase inhibitors
2014
Aptamers as targeted therapeutics: current potential and challenges
2016 Standout
Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges
2015
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
2011
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu
2012
IL-28B is a Key Regulator of B- and T-Cell Vaccine Responses against Influenza
2014 StandoutNobel
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities
2018
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
2014
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Antiangiogenic therapy in oncology: current status and future directions
2016
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
2010
Measuring the Relationship of Quality of Life and Health Status, Including Tumor Burden, Symptoms, and Biochemical Measures in Patients with Neuroendocrine Tumors
2011
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients
2013
Interferons as potential adjuvants in prophylactic vaccines
2010
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
2014
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
2014 StandoutNobel
Predictive in vivo animal models and translation to clinical trials
2012
Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion
2015
Tumour heterogeneity and resistance to cancer therapies
2017 Standout
Young-onset colorectal cancer
2023
The Emerging Roles of Pericytes in Modulating Tumor Microenvironment
2021
LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling
2013 StandoutNature
2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis
2016 Standout
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
2017 Standout
Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors
2015 StandoutNobel
Hepatocellular Carcinoma
2019 Standout
Management of glioblastoma: State of the art and future directions
2020 Standout
The side effects of platinum-based chemotherapy drugs: a review for chemists
2018 Standout
Cisplatin-Induced Long-Term Hearing Impairment Is Associated With Specific Glutathione S-Transferase Genotypes in Testicular Cancer Survivors
2007
Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway
2017 StandoutNobel
Diversity, Mechanisms, and Significance of Macrophage Plasticity
2019 Standout
Top advances of the year in colorectal cancer
2022
Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
2014
Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma
2016 StandoutNobel
Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination
2013
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
2014 Standout
Inositol Polyphosphate Multikinase Inhibits Angiogenesis via Inositol Pentakisphosphate-Induced HIF-1α Degradation
2017 StandoutNobel
Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
2012
Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta‐analysis of 36 clinical trials
2014
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
2017 Standout
Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes
2015
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Diabetic Neuropathy: A Position Statement by the American Diabetes Association
2016 Standout
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
2012
Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy
2020
Genetics and biology of pancreatic ductal adenocarcinoma
2016
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
2013
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18
2016
Works of Denis Smith being referenced
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial
2015
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
2021
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer
2017
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon α for advanced carcinoid tumors: FNCLCC–FFCD 9710
2009
Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study
2014
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
2022
Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene
2007
Predicting drug response and toxicity based on gene polymorphisms
2005
Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover.
2016
Effectiveness and safety in very elderly patients treated by bevacizumab (BV) plus chemotherapy in first-line therapy of metastatic colorectal cancer: Results of ETNA, a French cohort study.
2011
Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.
2020
Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val Gene Polymorphisms In Colorectal Cancer Patients: Relationships with Treatment Outcome
2007